Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Prostatic Neoplasms"" wg kryterium: Temat


Tytuł :
PROACTA: a survey on the actual attitude of the Italian radiation oncologists in the management and prescription of hormonal therapy in prostate cancer patients.
Autorzy :
Fersino S; Radiation Oncology Department, Azienda Provinciale per i Servizi Sanitari, Ospedale S.Chiara, Largo Medaglie d'oro, 9, 38122, Trento, Italy. .
Borghesi S; Radiotherapy Unit- Ospedale S. Donato e Santa Maria alla Gruccia, Azienda USL Toscana Sud, Arezzo, Italy.
Jereczek-Fossa BA; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.; Division of Radiotherapy, IEO European Institute of Oncology, IRCCS, Milan, Italy.
Arcangeli S; UOC Radioterapia ASST Monza, Università di Milano, Bicocca, Italy.
Mortellaro G; Department of Radiation Oncology, ARNAS Ospedale Civico, Palermo, Italy.
Magrini SM; Department of Radiation Oncology, University and Spedali Civili Hospital, Brescia, Italy.
Alongi F; Advanced Radiation Oncology Department, IRCCS Ospedale Sacro Cuore Don Calabria, Negrar-Verona, Italy.; University of Brescia, Brescia, Italy.
Pokaż więcej
Corporate Authors :
Uro-Oncology study group of Italian association of Radiotherapy and Clinical Oncology (AIRO)
Źródło :
La Radiologia medica [Radiol Med] 2021 Mar; Vol. 126 (3), pp. 460-465. Date of Electronic Publication: 2020 Aug 27.
Typ publikacji :
Journal Article
MeSH Terms :
Attitude of Health Personnel*
Radiation Oncologists*
Androgen Antagonists/*therapeutic use
Antineoplastic Agents, Hormonal/*therapeutic use
Health Care Surveys/*statistics & numerical data
Prostatic Neoplasms/*drug therapy
Androstenes/therapeutic use ; Combined Modality Therapy/methods ; Gonadotropin-Releasing Hormone/agonists ; Humans ; Italy ; Male ; Phenylthiohydantoin/analogs & derivatives ; Phenylthiohydantoin/therapeutic use ; Prostatectomy ; Prostatic Neoplasms/radiotherapy ; Prostatic Neoplasms/surgery ; Prostatic Neoplasms, Castration-Resistant/drug therapy ; Prostatic Neoplasms, Castration-Resistant/radiotherapy ; Risk Factors ; Salvage Therapy/methods
Czasopismo naukowe
Tytuł :
Obesity is Associated with Longer Survival Independent of Sarcopenia and Myosteatosis in Metastatic and/or Castrate-Resistant Prostate Cancer.
Autorzy :
Xu MC; Vanderbilt University School of Medicine, Nashville, Tennessee.
Huelster HL; Department of Urology, Vanderbilt University Medical Center, Nashville, Tennessee.
Hatcher JB; Vanderbilt University School of Medicine, Nashville, Tennessee.
Avulova S; Department of Urology, Vanderbilt University Medical Center, Nashville, Tennessee.
Stocks BT; Vanderbilt University School of Medicine, Nashville, Tennessee.
Glaser ZA; Vanderbilt University School of Medicine, Nashville, Tennessee.
Moses KA; Department of Urology, Vanderbilt University Medical Center, Nashville, Tennessee.
Silver HJ; Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Pokaż więcej
Źródło :
The Journal of urology [J Urol] 2021 Mar; Vol. 205 (3), pp. 800-805. Date of Electronic Publication: 2020 Oct 20.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms :
Obesity/*complications
Prostatic Neoplasms/*pathology
Sarcopenia/*complications
Adipose Tissue/diagnostic imaging ; Aged ; Aged, 80 and over ; Humans ; Male ; Middle Aged ; Muscle, Skeletal/diagnostic imaging ; Neoplasm Metastasis ; Neoplasm Staging ; Obesity/diagnostic imaging ; Prostatic Neoplasms, Castration-Resistant/pathology ; Retrospective Studies ; Sarcopenia/diagnostic imaging ; Survival Rate ; Tomography, X-Ray Computed
Czasopismo naukowe
Tytuł :
Comparative Analysis of Genomic Alterations across Castration Sensitive and Castration Resistant Prostate Cancer via Circulating Tumor DNA Sequencing.
Autorzy :
Fan L; Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Fei X; Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Zhu Y; Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Pan J; Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Sha J; Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Chi C; Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Gong Y; Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Du X; Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Zhou L; Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Dong B; Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Xue W; Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Pokaż więcej
Źródło :
The Journal of urology [J Urol] 2021 Feb; Vol. 205 (2), pp. 461-469. Date of Electronic Publication: 2020 Sep 08.
Typ publikacji :
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Sequence Analysis, DNA*
Circulating Tumor DNA/*blood
Circulating Tumor DNA/*genetics
Prostatic Neoplasms/*blood
Prostatic Neoplasms/*genetics
Aged ; Androgen Antagonists/therapeutic use ; Genomics ; Humans ; Male ; Middle Aged ; Prostatic Neoplasms/drug therapy ; Prostatic Neoplasms, Castration-Resistant/blood ; Prostatic Neoplasms, Castration-Resistant/genetics ; Retrospective Studies
Czasopismo naukowe
Tytuł :
4,4'-Diisothiocyanatostilbene-2,2'-disulfonate modulates voltage-gated K current and influences cell cycle arrest in androgen sensitive and insensitive human prostate cancer cell lines.
Autorzy :
George K; Department of Biomedical Engineering, Chennai Institute of Technology, Chennai, India.; Bio Engineering Lab, Department of Electronics and Instrumentation Engineering, Annamalai University, Annamalai Nagar, India.
Thomas NS; Department of Biochemistry and Biotechnology, Annamalai University, Annamalai Nagar, India.
Malathi R; Bio Engineering Lab, Department of Electronics and Instrumentation Engineering, Annamalai University, Annamalai Nagar, India.
Pokaż więcej
Źródło :
Toxicology mechanisms and methods [Toxicol Mech Methods] 2020 Jun; Vol. 30 (5), pp. 358-369. Date of Electronic Publication: 2020 Apr 01.
Typ publikacji :
Journal Article
MeSH Terms :
Prostatic Neoplasms*/metabolism
Prostatic Neoplasms*/pathology
4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid/*pharmacology
Antineoplastic Agents/*pharmacology
Cell Cycle Checkpoints/*drug effects
Potassium Channel Blockers/*pharmacology
Potassium Channels, Voltage-Gated/*antagonists & inhibitors
Receptors, Androgen/*metabolism
Apoptosis/drug effects ; Cell Proliferation/drug effects ; Dose-Response Relationship, Drug ; Humans ; Male ; Membrane Potentials/drug effects ; PC-3 Cells ; Patch-Clamp Techniques ; Potassium Channels, Voltage-Gated/metabolism ; Prostate/drug effects ; Prostate/metabolism ; Prostatic Neoplasms, Castration-Resistant/metabolism ; Prostatic Neoplasms, Castration-Resistant/pathology ; Tetraethylammonium/pharmacology
Czasopismo naukowe
Tytuł :
Treating Prostate Cancer by Antibody-Drug Conjugates.
Autorzy :
Rosellini M; Division of Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.
Santoni M; Oncology Unit, Macerata Hospital, 62100 Macerata, Italy.
Mollica V; Division of Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.
Rizzo A; Division of Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.
Cimadamore A; Section of Pathological Anatomy, School of Medicine, United Hospitals, Polytechnic University of the Marche Region, 60126 Ancona, Italy.
Scarpelli M; Section of Pathological Anatomy, School of Medicine, United Hospitals, Polytechnic University of the Marche Region, 60126 Ancona, Italy.
Storti N; Direzione Sanitaria Azienda Sanitaria Unica Regionale, 60122 Ancona, Italy.
Battelli N; Oncology Unit, Macerata Hospital, 62100 Macerata, Italy.
Montironi R; Section of Pathological Anatomy, School of Medicine, United Hospitals, Polytechnic University of the Marche Region, 60126 Ancona, Italy.
Massari F; Division of Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.
Pokaż więcej
Źródło :
International journal of molecular sciences [Int J Mol Sci] 2021 Feb 04; Vol. 22 (4). Date of Electronic Publication: 2021 Feb 04.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Antineoplastic Agents, Immunological/*therapeutic use
Immunoconjugates/*therapeutic use
Prostatic Neoplasms/*drug therapy
Animals ; Antineoplastic Agents, Immunological/pharmacology ; Biomarkers, Tumor ; Clinical Trials as Topic ; Disease Management ; Disease Susceptibility ; Humans ; Immunoconjugates/pharmacology ; Male ; Molecular Targeted Therapy ; Prognosis ; Prostatic Neoplasms/etiology ; Prostatic Neoplasms/mortality ; Prostatic Neoplasms/pathology ; Prostatic Neoplasms, Castration-Resistant/drug therapy ; Prostatic Neoplasms, Castration-Resistant/etiology ; Prostatic Neoplasms, Castration-Resistant/mortality ; Prostatic Neoplasms, Castration-Resistant/pathology ; Standard of Care ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Exosomes Promote the Transition of Androgen-Dependent Prostate Cancer Cells into Androgen-Independent Manner Through Up-Regulating the Heme Oxygenase-1.
Autorzy :
Zhang Y; Department of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou, People's Republic of China.; Guangzhou Key Laboratory of Inflammatory and Immune Diseases, Zhujiang Hospital, Southern Medical University, Guangzhou, People's Republic of China.
Chen B; Department of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou, People's Republic of China.; Guangzhou Key Laboratory of Inflammatory and Immune Diseases, Zhujiang Hospital, Southern Medical University, Guangzhou, People's Republic of China.
Xu N; Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Xu P; Department of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou, People's Republic of China.; Guangzhou Key Laboratory of Inflammatory and Immune Diseases, Zhujiang Hospital, Southern Medical University, Guangzhou, People's Republic of China.
Lin W; Department of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou, People's Republic of China.; Guangzhou Key Laboratory of Inflammatory and Immune Diseases, Zhujiang Hospital, Southern Medical University, Guangzhou, People's Republic of China.; Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Liu C; Department of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou, People's Republic of China.; Guangzhou Key Laboratory of Inflammatory and Immune Diseases, Zhujiang Hospital, Southern Medical University, Guangzhou, People's Republic of China.
Huang P; Department of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou, People's Republic of China.; Guangzhou Key Laboratory of Inflammatory and Immune Diseases, Zhujiang Hospital, Southern Medical University, Guangzhou, People's Republic of China.; Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Pokaż więcej
Źródło :
International journal of nanomedicine [Int J Nanomedicine] 2021 Jan 12; Vol. 16, pp. 315-327. Date of Electronic Publication: 2021 Jan 12 (Print Publication: 2021).
Typ publikacji :
Journal Article
MeSH Terms :
Androgens/*pharmacology
Exosomes/*metabolism
Heme Oxygenase-1/*metabolism
Prostatic Neoplasms/*pathology
Up-Regulation/*drug effects
Animals ; Cell Line, Tumor ; Disease Progression ; Exosomes/ultrastructure ; Gene Expression Regulation, Neoplastic ; Humans ; Male ; Mice, Inbred NOD ; Mice, SCID ; Prostatic Neoplasms/genetics ; Prostatic Neoplasms, Castration-Resistant/genetics ; Prostatic Neoplasms, Castration-Resistant/pathology ; Receptors, Androgen/metabolism ; Tumor Microenvironment
Czasopismo naukowe
Tytuł :
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Autorzy :
Jakob T; Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Tesfamariam YM; Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Macherey S; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Cochrane Haematological Malignancies, Cologne, Germany.
Kuhr K; Institute of Medical Statistics and Computational Biology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Adams A; Institute of Medical Statistics and Computational Biology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Monsef I; Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Heidenreich A; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Department of Urology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Skoetz N; Cochrane Cancer, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Pokaż więcej
Źródło :
The Cochrane database of systematic reviews [Cochrane Database Syst Rev] 2020 Dec 03; Vol. 12. Cochrane AN: CD013020. Date of Electronic Publication: 2020 Dec 03.
Typ publikacji :
Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review
MeSH Terms :
Bone Density Conservation Agents/*therapeutic use
Bone Neoplasms/*drug therapy
Bone Neoplasms/*secondary
Denosumab/*therapeutic use
Diphosphonates/*therapeutic use
Prostatic Neoplasms/*pathology
RANK Ligand/*antagonists & inhibitors
Adult ; Alendronate/adverse effects ; Alendronate/therapeutic use ; Antineoplastic Agents, Hormonal/therapeutic use ; Bisphosphonate-Associated Osteonecrosis of the Jaw/etiology ; Bone Density Conservation Agents/adverse effects ; Clodronic Acid/adverse effects ; Clodronic Acid/therapeutic use ; Denosumab/adverse effects ; Diphosphonates/adverse effects ; Etidronic Acid/adverse effects ; Etidronic Acid/therapeutic use ; Humans ; Male ; Network Meta-Analysis ; Pamidronate/adverse effects ; Pamidronate/therapeutic use ; Prostatic Neoplasms/drug therapy ; Prostatic Neoplasms, Castration-Resistant/pathology ; Quality of Life ; Randomized Controlled Trials as Topic ; Risedronic Acid/adverse effects ; Risedronic Acid/therapeutic use ; Zoledronic Acid/adverse effects ; Zoledronic Acid/therapeutic use
Czasopismo naukowe
Tytuł :
EGFR as a stable marker of prostate cancer dissemination to bones.
Autorzy :
Nastały P; Laboratory of Translational Oncology, Institute of Medical Biotechnology and Experimental Oncology, Medical University of Gdańsk, Gdańsk, Poland.; FIRC (Italian Foundation for Cancer Research) Institute of Molecular Oncology (IFOM), Milan, Italy.
Stoupiec S; Department of Tumour Biology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.
Popęda M; Laboratory of Translational Oncology, Institute of Medical Biotechnology and Experimental Oncology, Medical University of Gdańsk, Gdańsk, Poland.
Smentoch J; Laboratory of Translational Oncology, Institute of Medical Biotechnology and Experimental Oncology, Medical University of Gdańsk, Gdańsk, Poland.
Schlomm T; Department of Urology, Charité University Hospital Berlin, Berlin, Germany.
Morrissey C; Department of Urology, University of Washington, Seattle, WA, USA.
Żaczek AJ; Laboratory of Translational Oncology, Institute of Medical Biotechnology and Experimental Oncology, Medical University of Gdańsk, Gdańsk, Poland.
Beyer B; Martini-Clinic, Prostate Cancer Center and Section for Translational Prostate Cancer Research at the Clinic of Urology at University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Tennstedt P; Martini-Clinic, Prostate Cancer Center and Section for Translational Prostate Cancer Research at the Clinic of Urology at University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Graefen M; Martini-Clinic, Prostate Cancer Center and Section for Translational Prostate Cancer Research at the Clinic of Urology at University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Eltze E; Institute of Pathology Saarbruecken-Rastpfuhl, Saarbruecken, Germany.
Maiuri P; FIRC (Italian Foundation for Cancer Research) Institute of Molecular Oncology (IFOM), Milan, Italy.
Semjonow A; Department of Urology, Prostate Center University Clinic Münster, Münster, Germany.
Pantel K; Department of Tumour Biology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.
Brandt B; University Medical Centre Schleswig-Holstein, Kiel, Germany.
Bednarz-Knoll N; Laboratory of Translational Oncology, Institute of Medical Biotechnology and Experimental Oncology, Medical University of Gdańsk, Gdańsk, Poland. .; Department of Tumour Biology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany. .
Pokaż więcej
Źródło :
British journal of cancer [Br J Cancer] 2020 Dec; Vol. 123 (12), pp. 1767-1774. Date of Electronic Publication: 2020 Sep 09.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Biomarkers, Tumor/*metabolism
Bone Neoplasms/*secondary
Neoplastic Cells, Circulating/*metabolism
Prostatic Neoplasms/*pathology
Biomarkers, Tumor/genetics ; Bone Neoplasms/mortality ; Cell Movement ; Collagen Type I/genetics ; Epithelial-Mesenchymal Transition ; ErbB Receptors/genetics ; ErbB Receptors/metabolism ; Feasibility Studies ; Flow Cytometry ; Humans ; Immunohistochemistry ; Male ; Neoplastic Cells, Circulating/pathology ; Prostatic Neoplasms/metabolism ; Prostatic Neoplasms/mortality ; Prostatic Neoplasms, Castration-Resistant/metabolism ; Prostatic Neoplasms, Castration-Resistant/mortality ; Prostatic Neoplasms, Castration-Resistant/pathology ; Vimentin/metabolism
Czasopismo naukowe
Tytuł :
Population-based Assessment of Intermittent Androgen Deprivation Therapy Utilization for Relapsed, Nonmetastatic, Hormone-sensitive Adenocarcinoma of the Prostate.
Autorzy :
Janzen BW; Postgraduate Medical Education.
Ong A; Section of Radiation Oncology.
Penner M; Canadian Mennonite University, Winnipeg, MB, Canada.
Koul R; Section of Radiation Oncology.
Dubey A; Section of Radiation Oncology.
Ahmed S; Section of Radiation Oncology.
Bashir B; Section of Radiation Oncology.
Chowdhury A; Section of Radiation Oncology.
Dawe DE; Section of Hematology/Oncology, Department of Internal Medicine.; Section of Urology, Department of Surgery, Max Rady College of Medicine.
Nayak J; Section of Urology, Department of Surgery, Max Rady College of Medicine.
Kim JO; Section of Radiation Oncology.; Research Institute in Hematology and Oncology, CancerCare Manitoba, University of Manitoba.
Pokaż więcej
Źródło :
American journal of clinical oncology [Am J Clin Oncol] 2020 Dec 01; Vol. 43 (12), pp. 865-871.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Adenocarcinoma/*drug therapy
Androgen Antagonists/*therapeutic use
Antineoplastic Agents, Hormonal/*therapeutic use
Prostatic Neoplasms/*drug therapy
Adenocarcinoma/mortality ; Adenocarcinoma/pathology ; Adenocarcinoma/therapy ; Aged ; Aged, 80 and over ; Humans ; Kallikreins/blood ; Male ; Manitoba/epidemiology ; Marital Status ; Middle Aged ; Neoplasm Recurrence, Local/drug therapy ; Prostate-Specific Antigen/blood ; Prostatic Neoplasms/mortality ; Prostatic Neoplasms/pathology ; Prostatic Neoplasms/therapy ; Prostatic Neoplasms, Castration-Resistant/drug therapy ; Prostatic Neoplasms, Castration-Resistant/pathology ; Radiation Oncologists ; Retrospective Studies ; Survival Analysis
Czasopismo naukowe
Tytuł :
Doublecortin Expression in Prostate Adenocarcinoma and Neuroendocrine Tumors.
Autorzy :
Tabrizi S; Department of Radiation Oncology, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston, Massachusetts. Electronic address: .
Alshalalfa M; Department of Radiation Oncology, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston, Massachusetts; Department of Radiation Oncology, University of California, San Francisco, California.
Mahal BA; Department of Radiation Oncology, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston, Massachusetts.
Davicioni E; Decipher Biosciences, San Diego, California.
Liu Y; Decipher Biosciences, San Diego, California.
Mouw KW; Department of Radiation Oncology, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston, Massachusetts.
Feng F; Department of Radiation Oncology, University of California, San Francisco, California.
Nguyen PL; Department of Radiation Oncology, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston, Massachusetts.
Muralidhar V; Department of Radiation Oncology, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston, Massachusetts.
Pokaż więcej
Źródło :
International journal of radiation oncology, biology, physics [Int J Radiat Oncol Biol Phys] 2020 Nov 15; Vol. 108 (4), pp. 936-940. Date of Electronic Publication: 2020 Jun 22.
Typ publikacji :
Journal Article
MeSH Terms :
Adenocarcinoma/*metabolism
Microtubule-Associated Proteins/*metabolism
Neoplasm Proteins/*metabolism
Neuroendocrine Tumors/*metabolism
Neuropeptides/*metabolism
Prostatic Neoplasms/*metabolism
Adenocarcinoma/mortality ; Adenocarcinoma/pathology ; Confidence Intervals ; Humans ; Linear Models ; Male ; Neuroendocrine Tumors/mortality ; Neuroendocrine Tumors/pathology ; Prostate/metabolism ; Prostatic Neoplasms/mortality ; Prostatic Neoplasms/pathology ; Prostatic Neoplasms, Castration-Resistant/metabolism ; Prostatic Neoplasms, Castration-Resistant/mortality ; Prostatic Neoplasms, Castration-Resistant/pathology ; Statistics, Nonparametric
Czasopismo naukowe
Tytuł :
Cellular growth factors as prospective therapeutic targets for combination therapy in androgen independent prostate cancer (AIPC).
Autorzy :
Jonnalagadda B; Department of Biomedical Sciences, Sri Ramachandra Institute of Higher Education and Research, Chennai, India.
Arockiasamy S; Department of Biomedical Sciences, Sri Ramachandra Institute of Higher Education and Research, Chennai, India. Electronic address: .
Krishnamoorthy S; Department of Urology, Sri Ramachandra Medical Centre, Sri Ramachandra Institute of Higher Education and Research, Chennai, India.
Pokaż więcej
Źródło :
Life sciences [Life Sci] 2020 Oct 15; Vol. 259, pp. 118208. Date of Electronic Publication: 2020 Aug 04.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Prostatic Neoplasms, Castration-Resistant/*drug therapy
Receptors, Androgen/*metabolism
Androgens/metabolism ; Combined Modality Therapy/methods ; Disease Progression ; Drug Therapy, Combination/methods ; Humans ; Intercellular Signaling Peptides and Proteins/metabolism ; Male ; Prospective Studies ; Prostate/metabolism ; Prostatic Neoplasms/drug therapy ; Prostatic Neoplasms, Castration-Resistant/metabolism ; Receptors, Androgen/drug effects ; Signal Transduction/drug effects
Czasopismo naukowe
Tytuł :
Neuroendocrine differentiation in usual-type prostatic adenocarcinoma: Molecular characterization and clinical significance.
Autorzy :
Kaur H; Department of Pathology, School of Medicine, Johns Hopkins University, Baltimore, Maryland.
Samarska I; Department of Pathology, School of Medicine, Johns Hopkins University, Baltimore, Maryland.
Lu J; Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland.
Faisal F; Department of Urology, School of Medicine, Johns Hopkins University, Baltimore, Maryland.
Maughan BL; Department of Oncology, School of Medicine, Johns Hopkins University, Baltimore, Maryland.; Division of Medical Oncology, Huntsman Cancer Institute, The University of Utah, Salt Lake City, Utah.
Murali S; Department of Pathology, School of Medicine, Johns Hopkins University, Baltimore, Maryland.
Asrani K; Department of Pathology, School of Medicine, Johns Hopkins University, Baltimore, Maryland.
Alshalalfa M; Division of Bioinformatics, GenomeDx Biosciences, Vancouver, Canada.
Antonarakis ES; Department of Oncology, School of Medicine, Johns Hopkins University, Baltimore, Maryland.
Epstein JI; Department of Pathology, School of Medicine, Johns Hopkins University, Baltimore, Maryland.; Department of Urology, School of Medicine, Johns Hopkins University, Baltimore, Maryland.; Department of Oncology, School of Medicine, Johns Hopkins University, Baltimore, Maryland.
Joshu CE; Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland.
Schaeffer EM; Department of Urology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
Mosquera JM; Department of Pathology, Weill Cornell Medicine, New York, New York.
Lotan TL; Department of Pathology, School of Medicine, Johns Hopkins University, Baltimore, Maryland.; Department of Urology, School of Medicine, Johns Hopkins University, Baltimore, Maryland.; Department of Oncology, School of Medicine, Johns Hopkins University, Baltimore, Maryland.
Pokaż więcej
Źródło :
The Prostate [Prostate] 2020 Sep; Vol. 80 (12), pp. 1012-1023. Date of Electronic Publication: 2020 Jul 10.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms :
Neuroendocrine Cells/*pathology
Neuroendocrine Tumors/*pathology
Prostatic Neoplasms/*pathology
Adenocarcinoma/genetics ; Adenocarcinoma/metabolism ; Adenocarcinoma/pathology ; Carcinoma, Small Cell/genetics ; Carcinoma, Small Cell/metabolism ; Carcinoma, Small Cell/pathology ; Cell Differentiation/physiology ; Cohort Studies ; Humans ; Immunohistochemistry ; Male ; Middle Aged ; Neuroendocrine Cells/metabolism ; Neuroendocrine Tumors/genetics ; Neuroendocrine Tumors/metabolism ; PTEN Phosphohydrolase/genetics ; PTEN Phosphohydrolase/metabolism ; Prostatic Neoplasms/genetics ; Prostatic Neoplasms/metabolism ; Prostatic Neoplasms, Castration-Resistant/genetics ; Prostatic Neoplasms, Castration-Resistant/pathology ; Receptors, Androgen/biosynthesis ; Receptors, Androgen/genetics ; Receptors, Androgen/metabolism ; Retinoblastoma Binding Proteins/genetics ; Retinoblastoma Binding Proteins/metabolism ; Retrospective Studies ; Signal Transduction ; Tumor Suppressor Protein p53/genetics ; Tumor Suppressor Protein p53/metabolism ; Ubiquitin-Protein Ligases/genetics ; Ubiquitin-Protein Ligases/metabolism
Czasopismo naukowe
Tytuł :
Can ultrasound irradiation be a therapeutic option for prostate cancer?
Autorzy :
Maeshige N; Department of Rehabilitation Science, Kobe University Graduate School of Health Science, Kobe, Japan.; John B. Little Center for Radiation Sciences, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Kitagawa K; Department of Advanced Medical Science, Kobe University Graduate School of Science, Technology and Innovation, Kobe, Japan.; Department of International Health, Kobe University Graduate School of Health Sciences, Kobe, Japan.
Yamasaki S; Department of International Health, Kobe University Graduate School of Health Sciences, Kobe, Japan.
Ishii A; Department of International Health, Kobe University Graduate School of Health Sciences, Kobe, Japan.
Shirakawa T; Department of Advanced Medical Science, Kobe University Graduate School of Science, Technology and Innovation, Kobe, Japan.; Department of International Health, Kobe University Graduate School of Health Sciences, Kobe, Japan.
Yang YM; Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan.
Sung SY; The Ph.D. Program for Translational Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.
Chen KC; Department of Urology, Taipei Medical University-Shuang Ho Hospital, Taipei, Taiwan.
Yuan ZM; John B. Little Center for Radiation Sciences, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Shigemura K; Department of International Health, Kobe University Graduate School of Health Sciences, Kobe, Japan.; Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan.
Fujisawa M; Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan.
Pokaż więcej
Źródło :
The Prostate [Prostate] 2020 Sep; Vol. 80 (12), pp. 986-992. Date of Electronic Publication: 2020 Jun 18.
Typ publikacji :
Journal Article
MeSH Terms :
Prostatic Neoplasms/*radiotherapy
Ultrasonic Therapy/*methods
Apoptosis/radiation effects ; Cell Line, Tumor ; Cell Proliferation/radiation effects ; Cell Survival/radiation effects ; Humans ; Male ; PC-3 Cells ; Prostatic Neoplasms/pathology ; Prostatic Neoplasms, Castration-Resistant/pathology ; Prostatic Neoplasms, Castration-Resistant/radiotherapy
Czasopismo naukowe
Tytuł :
Pelvic exenteration surgery in patients with locally advanced castration-naïve and castration-resistant, symptomatic prostate cancer.
Autorzy :
Heidenreich A; Department of Urology, Uro-Oncology, Robot-Assisted and Specialized Urological Surgery, University Hospital Cologne, Cologne, Germany.; Department of Urology, Medical University Vienna, Vienna, Austria.
Bludau M; Department of Visceral and Cancer Surgery, University Hospital of Cologne, Cologne, Germany.
Bruns C; Department of Visceral and Cancer Surgery, University Hospital of Cologne, Cologne, Germany.
Nestler T; Department of Urology, Uro-Oncology, Robot-Assisted and Specialized Urological Surgery, University Hospital Cologne, Cologne, Germany.
Porres D; Department of Urology, Uro-Oncology, Robot-Assisted and Specialized Urological Surgery, University Hospital Cologne, Cologne, Germany.
Pfister DJKP; Department of Urology, Uro-Oncology, Robot-Assisted and Specialized Urological Surgery, University Hospital Cologne, Cologne, Germany.
Pokaż więcej
Źródło :
BJU international [BJU Int] 2020 Sep; Vol. 126 (3), pp. 342-349. Date of Electronic Publication: 2020 May 16.
Typ publikacji :
Journal Article
MeSH Terms :
Pelvic Exenteration*
Prostatectomy/*methods
Prostatic Neoplasms/*surgery
Adult ; Aged ; Aged, 80 and over ; Humans ; Male ; Middle Aged ; Neoplasm Staging ; Prostatic Neoplasms/diagnosis ; Prostatic Neoplasms/pathology ; Prostatic Neoplasms, Castration-Resistant/diagnosis ; Prostatic Neoplasms, Castration-Resistant/pathology ; Prostatic Neoplasms, Castration-Resistant/surgery ; Retrospective Studies ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Systematic Literature Review of the Epidemiology of Advanced Prostate Cancer and Associated Homologous Recombination Repair Gene Alterations.
Autorzy :
Shore N; Carolina Urologic Research Center , Myrtle Beach, South Carolina.
Oliver L; Adelphi Values PROVE , Manchester, UK.
Shui I; Merck & Co.Inc., Kenilworth, New Jersey.
Gayle A; AstraZeneca , Cambridge, UK.
Wong OY; Adelphi Values PROVE , Manchester, UK.
Kim J; Merck & Co.Inc., Kenilworth, New Jersey.
Payne S; AstraZeneca , Cambridge, UK.
Amin S; AstraZeneca , Cambridge, UK.
Ghate S; Merck & Co.Inc., Kenilworth, New Jersey.
Pokaż więcej
Źródło :
The Journal of urology [J Urol] 2021 Apr; Vol. 205 (4), pp. 977-986. Date of Electronic Publication: 2020 Dec 17.
Typ publikacji :
Journal Article; Systematic Review
MeSH Terms :
Recombinational DNA Repair*
Biomarkers, Tumor/*genetics
Prostatic Neoplasms, Castration-Resistant/*epidemiology
Prostatic Neoplasms, Castration-Resistant/*genetics
Circulating Tumor DNA/genetics ; DNA Mutational Analysis ; Disease Progression ; Genetic Predisposition to Disease ; Germ-Line Mutation ; Humans ; Male ; Neoplasm Metastasis ; Prevalence ; Prognosis ; Prostate-Specific Antigen/blood ; Prostatic Neoplasms, Castration-Resistant/pathology
Czasopismo naukowe
Tytuł :
Selecting Patients with Favorable Risk, Grade Group 2 Prostate Cancer for Active Surveillance-Does Magnetic Resonance Imaging Have a Role?
Autorzy :
Stonier T; Department of Surgery (Urology Service), Memorial Sloan Kettering Cancer Center, New York, New York.; St George's Hospital, London, UK.
Tin AL; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
Sjoberg DD; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
Jibara G; Department of Surgery (Urology Service), Memorial Sloan Kettering Cancer Center, New York, New York.
Vickers AJ; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
Fine S; Department of Surgery (Urology Service), Memorial Sloan Kettering Cancer Center, New York, New York.
Eastham J; Department of Surgery (Urology Service), Memorial Sloan Kettering Cancer Center, New York, New York.
Pokaż więcej
Źródło :
The Journal of urology [J Urol] 2021 Apr; Vol. 205 (4), pp. 1063-1068. Date of Electronic Publication: 2020 Nov 20.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms :
Patient Selection*
Prostatic Neoplasms/*diagnostic imaging
Prostatic Neoplasms/*surgery
Aged ; Biopsy ; Humans ; Male ; Middle Aged ; Multiparametric Magnetic Resonance Imaging ; Neoplasm Grading ; Neoplasm Staging ; Prostatectomy ; Prostatic Neoplasms/pathology ; Retrospective Studies ; Risk Factors ; Watchful Waiting
Czasopismo naukowe
Tytuł :
Oncologic Outcomes after Localized Prostate Cancer Treatment: Associations with Pretreatment Prostate Magnetic Resonance Imaging Findings.
Autorzy :
Wibmer AG; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
Chaim J; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
Lakhman Y; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
Lefkowitz RA; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
Nincevic J; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
Nikolovski I; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
Sala E; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
Gonen M; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
Carlsson SV; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.; Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, New York.; Department of Urology, Sahlgrenska Academy at University of Gothenburg, Institute of Clinical Sciences, Gothenburg, Sweden.
Fine SW; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Zelefsky MJ; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
Scardino P; Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Hricak H; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
Vargas HA; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
Pokaż więcej
Źródło :
The Journal of urology [J Urol] 2021 Apr; Vol. 205 (4), pp. 1055-1062. Date of Electronic Publication: 2020 Nov 18.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms :
Magnetic Resonance Imaging/*methods
Prostatic Neoplasms/*diagnostic imaging
Prostatic Neoplasms/*therapy
Adult ; Aged ; Aged, 80 and over ; Humans ; Male ; Middle Aged ; Neoplasm Invasiveness ; Prognosis ; Prostatectomy ; Prostatic Neoplasms/mortality ; Radiotherapy ; Retrospective Studies ; Survival Rate
Czasopismo naukowe
Tytuł :
Prognostic and Theranostic Applications of Positron Emission Tomography for a Personalized Approach to Metastatic Castration-Resistant Prostate Cancer.
Autorzy :
Filippi L; Department of Nuclear Medicine, 'Santa Maria Goretti' Hospital, Via Antonio Canova, 04100 Latina, Italy.
Frantellizzi V; Department of Radiological Sciences, Oncology and Anatomical Pathology, Sapienza University of Rome, viale Regina Elena 324, 00100 Rome, Italy.
Chiaravalloti A; Department of Biomedicine and Prevention, University Tor Vergata, Viale Oxford 81, 00133 Rome, Italy.; IRCCS Neuromed, 86077 Pozzilli, Italy.
Pontico M; Department of Radiological Sciences, Oncology and Anatomical Pathology, Sapienza University of Rome, viale Regina Elena 324, 00100 Rome, Italy.
De Feo MS; Department of Radiological Sciences, Oncology and Anatomical Pathology, Sapienza University of Rome, viale Regina Elena 324, 00100 Rome, Italy.
Corica F; Department of Radiological Sciences, Oncology and Anatomical Pathology, Sapienza University of Rome, viale Regina Elena 324, 00100 Rome, Italy.
Montebello M; Department of Radiological Sciences, Oncology and Anatomical Pathology, Sapienza University of Rome, viale Regina Elena 324, 00100 Rome, Italy.
Schillaci O; Department of Biomedicine and Prevention, University Tor Vergata, Viale Oxford 81, 00133 Rome, Italy.; IRCCS Neuromed, 86077 Pozzilli, Italy.
De Vincentis G; Department of Radiological Sciences, Oncology and Anatomical Pathology, Sapienza University of Rome, viale Regina Elena 324, 00100 Rome, Italy.
Bagni O; Department of Nuclear Medicine, 'Santa Maria Goretti' Hospital, Via Antonio Canova, 04100 Latina, Italy.
Pokaż więcej
Źródło :
International journal of molecular sciences [Int J Mol Sci] 2021 Mar 16; Vol. 22 (6). Date of Electronic Publication: 2021 Mar 16.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Positron-Emission Tomography*
Precision Medicine*
Prostatic Neoplasms, Castration-Resistant/*diagnosis
Prostatic Neoplasms, Castration-Resistant/*therapy
Biomarkers, Tumor/metabolism ; Humans ; Male ; Neoplasm Metastasis ; Prognosis ; Prostatic Neoplasms, Castration-Resistant/diagnostic imaging ; Prostatic Neoplasms, Castration-Resistant/pathology
Czasopismo naukowe
Tytuł :
Immune checkpoint-related serum proteins and genetic variants predict outcomes of localized prostate cancer, a cohort study.
Autorzy :
Wang Q; Department of Surgical Oncology, Affiliated Sir Run Run Shaw Hospital and Department of Epidemiology and Health Statistics School of Public Health, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Ye Y; Center for Clinical Big Data and Analytics, Bioinformatics and Big Data, The Second Affiliated Hospital and School of Public Health, Zhejiang University School of Medicine, 866 Yuhangtang Rd, Hangzhou, 310058, PR China.
Yu H; Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Lin SH; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA.
Tu H; Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Liang D; Department of Pharmaceutical Sciences, Texas Southern University, Houston, TX, USA.
Chang DW; Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Huang M; Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Wu X; Center for Clinical Big Data and Analytics, Bioinformatics and Big Data, The Second Affiliated Hospital and School of Public Health, Zhejiang University School of Medicine, 866 Yuhangtang Rd, Hangzhou, 310058, PR China. .
Pokaż więcej
Źródło :
Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2021 Mar; Vol. 70 (3), pp. 701-712. Date of Electronic Publication: 2020 Sep 09.
Typ publikacji :
Journal Article
MeSH Terms :
Genetic Variation*
Immune Checkpoint Proteins/*metabolism
Prostatic Neoplasms/*etiology
Prostatic Neoplasms/*metabolism
Aged ; Biomarkers ; Cohort Studies ; Disease Progression ; Disease Susceptibility ; Genotype ; Humans ; Immune Checkpoint Proteins/blood ; Immune Checkpoint Proteins/genetics ; Immunophenotyping ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Neoplasm Staging ; Prognosis ; Prostatic Neoplasms/mortality ; Prostatic Neoplasms/pathology ; Receptors, Antigen, B-Cell/metabolism
Czasopismo naukowe
Tytuł :
Use of the MyProstateScore Test to Rule Out Clinically Significant Cancer: Validation of a Straightforward Clinical Testing Approach.
Autorzy :
Tosoian JJ; Department of Urology, University of Michigan, Ann Arbor, Michigan.; Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan.; Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan.
Trock BJ; Johns Hopkins Brady Urological Institute, Baltimore, Maryland.
Morgan TM; Department of Urology, University of Michigan, Ann Arbor, Michigan.; Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan.
Salami SS; Department of Urology, University of Michigan, Ann Arbor, Michigan.; Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan.; Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan.
Tomlins SA; Department of Urology, University of Michigan, Ann Arbor, Michigan.; Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan.; Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan.
Spratt DE; Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan.; Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan.
Siddiqui J; Department of Urology, University of Michigan, Ann Arbor, Michigan.; Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan.
Kunju LP; Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan.; Department of Pathology, University of Michigan, Ann Arbor, Michigan.
Botbyl R; Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan.
Chopra Z; Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan.
Pandian B; Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan.
Eyrich NW; Department of Urology, University of Michigan, Ann Arbor, Michigan.
Longton G; Biostatistics Program, Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Zheng Y; Biostatistics Program, Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Palapattu GS; Department of Urology, University of Michigan, Ann Arbor, Michigan.; Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan.
Wei JT; Department of Urology, University of Michigan, Ann Arbor, Michigan.; Dow Division of Health Services Research, University of Michigan, Ann Arbor, Michigan.
Niknafs YS; Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan.
Chinnaiyan AM; Department of Urology, University of Michigan, Ann Arbor, Michigan.; Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan.; Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan.; Department of Pathology, University of Michigan, Ann Arbor, Michigan.; Howard Hughes Medical Institute, University of Michigan, Ann Arbor, Michigan.
Pokaż więcej
Źródło :
The Journal of urology [J Urol] 2021 Mar; Vol. 205 (3), pp. 732-739. Date of Electronic Publication: 2020 Oct 20.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Validation Study
MeSH Terms :
Antigens, Neoplasm/*urine
Prostate-Specific Antigen/*blood
Prostatic Neoplasms/*blood
Prostatic Neoplasms/*urine
Serine Endopeptidases/*urine
Aged ; Biomarkers, Tumor/blood ; Biomarkers, Tumor/urine ; Biopsy ; Digital Rectal Examination ; Humans ; Male ; Middle Aged ; Neoplasm Grading ; Predictive Value of Tests ; Prospective Studies ; Prostatic Neoplasms/pathology ; Referral and Consultation/statistics & numerical data ; Risk Assessment/methods ; Sensitivity and Specificity
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies